Search
Semaglutide Treatment Options for Type 2 Diabetes
A collection of 94 research studies in Type 2 Diabetes where Semaglutide is the interventional treatment. Semaglutide is used for conditions such as Type 2 Diabetes.
25 - 36 of 94
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Type 2 Diabetes
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
Completed
We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys.
Participants will either get semaglutide or placebo (a 'dummy' medicine) - which treatment participants get is decided by chance.
Semaglutide is a medicine doctors can prescribe in some countries for the treatment of type 2 diabetes.
Participants will get the study medicine in a pen. Participan... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2025
Locations: Academic Medical Research Institute, Los Angeles, California +30 locations
Conditions: Diabetes Mellitus, Type 2, Chronic Kidney Disease
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
Recruiting
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Gender:
ALL
Ages:
All
Trial Updated:
04/25/2025
Locations: Research Site, Mobile, Alabama +120 locations
Conditions: Diabetes Mellitus, Type 2
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Active Not Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: University of Alabama - Department of Nutrition Sciences, Birmingham, Alabama +76 locations
Conditions: Diabetes Mellitus, Type 2
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
Completed
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.
Gender:
ALL
Ages:
Between 65 years and 90 years
Trial Updated:
04/22/2025
Locations: UT Health San Antonio, San Antonio, Texas
Conditions: Aging, Diabetes Mellitus, Type 2, PreDiabetes, Overweight and Obesity
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
Completed
This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance.
The study will last for about 1½ years. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2025
Locations: John Muir Physicians Network, Concord, California +169 locations
Conditions: Overweight, Obesity, Type 2 Diabetes Mellitus
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Active Not Recruiting
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Absolute Clinical Research, Phoenix, Arizona +130 locations
Conditions: Type 2 Diabetes
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
Recruiting
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other information about type 2 diabetes and obesity.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2025
Locations: University Health - Texas Diabetic Institute, San Antonio, Texas +1 locations
Conditions: Spinal Cord Injuries, Type 2 Diabetes
Triple Therapy in T1DM
Active Not Recruiting
To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/31/2025
Locations: Diabetes and Endocrinology Research Center of WNY, Williamsville, New York
Conditions: Type 1 Diabetes Mellitus
Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)
Completed
This study plans to learn more about the effect of semaglutide once weekly on intestinal permeability in individuals with type 2 diabetes.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
03/17/2025
Locations: University of Colorado Anschutz, Aurora, Colorado
Conditions: Type 2 Diabetes, Chronic Inflammation, Intestinal Permeability
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
Completed
The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will get semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Dr. Terence Hart, Tuscumbia, Alabama +412 locations
Conditions: Diabetes Mellitus, Type 2
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes
Completed
This study compares three doses of once daily semaglutide tablets in people with type 2 diabetes who were previously treated with other oral anti-diabetic medicines. Participants will be initiated on the lowest starting dose of 3 mg and gradually increased until they reach the final trial dose of 14 mg, 25 mg or 50 mg once daily semaglutide tablets. The final three doses will be randomized (i.e., decided by chance). Participants will be administered one tablet per day for 68 weeks. Women cannot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: American Clinical Trials, Buena Park, California +180 locations
Conditions: Diabetes Mellitus, Type 2
A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets
Completed
Participants in the study, will receive the study drug once daily for 10 days in tablet form for oral (by mouth) intake. On day 1 to 5 the tablet will contain 3 mg semaglutide, and on day 6-10 the tablet will contain 7 mg semaglutide.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: ICON Early Phase Services, LLC, San Antonio, Texas +1 locations
Conditions: Diabetes Mellitus, Type 2
25 - 36 of 94